Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

Organogenesis gets an FDA approval, but its shares dive

Article Abstract:

Organogenesis Inc.'s Apligraf artificial skin product has been approved by the Food and Drug Administration (FDA). However, the value of the company's stock fell by 13% despite the approval. The Apligraf product is designed to treat venous leg ulcers or wounds caused by poor blood flow. Profit-taking among bullish investors was believed to be the reason for the drop in share value. Also contributing to the drop were predictions that the Apligraf would turn out to be a disappointment.

Comment:

Apligraf artificial skin product approved by the Food and Drug Administration (FDA); co's stocks fall 13% despite approval

Author: Johannes, Laura
Publisher: Dow Jones & Company, Inc.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
Product information, Surgical Appliance and Supplies Manufacturing, Dermatological Prostheses, Artificial skin, Organogenesis Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Interneuron agrees on settlement of lawsuits

Article Abstract:

Interneuron Pharmaceuticals Inc. has reached an agreement in principle to a $70 million settlement for all of the lawsuits arrayed against it. Interneuron is the firm that developed the Redux diet pill that was recalled in 1997 because of major safety concerns. The company also agreed to an unspecified amount of liability-insurance funds under the agreement. The funds will be paid between 1998 and 2005.

Comment:

Reaches agreement in principle to a $70 million settlement for all of the lawsuits arrayed against it

Author: Johannes, Laura, Schmitt, Richard B.
Publisher: Dow Jones & Company, Inc.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
Legal issues & crime, Pharmaceutical Preparation Manufacturing, Central Nervous System Prep, Central nervous system agents, Interneuron Pharmaceuticals Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Gillette Co. sees strong early sales for its new razor

Article Abstract:

Gillette Co. announced that its new triple-blade Mach 3 razor had become the top selling product in the US razor industry during its first full week on the market. The Mach 3 captured 35% of the revenues that US customers spent on razors. The sales were for the seven days that ended on July 4, 1998. Gillette claimed that the Mach 3 sold twice as many units as any other razor product.

Comment:

New triple-blade Mach 3 razor becomes the top selling product in the US razor industry during its first full week on the market

Author: Johannes, Laura
Publisher: Dow Jones & Company, Inc.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
Sales & consumption, Cutlery and Flatware (except Precious) Manufacturing, Geographic, Razor Blades & Razors ex Electric, Gillette Co., Razors

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Article
Similar abstracts:
  • Abstracts: 2 book giants in global deal to sell titles via Internet. Microsoft and Barnes & Noble join forces. The next trick for Amazon.com: auctions; the leading on-line bookseller hopes to pose a challenge to eBay
  • Abstracts: Old rivals fight for new turf-biotech crops. DuPont agrees to purchase of seed firm. AgrEvo to buy Cargill seed unit for $650 million
  • Abstracts: Viagra's lesson: new drugs, unknown risks. European Commission is set to clear Pfizer's Viagra for sale in EU nations
  • Abstracts: DuPont puts stock in global security force. DuPont Merck sued over licensing deal. DuPont buys out Merck
  • Abstracts: Entergy names Leonard CEO, Hintz president. Entergy's $80 million offer for Pilgrim beats out rival Peco for nuclear plant
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.